Continuous bioprocessing market to reach $1.01 billion by 2030

The continuous bioprocessing market is projected to grow from $0.46 billion in 2026 to $1.01 billion by 2030, driven by demand for personalized medicine, biologics production and scalable manufacturing. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - Continuous bioprocessing is moving from a niche manufacturing approach to a core platform for biologics, cell therapies and personalized medicine. - The market’s projected rise to $1.01 billion by 2030 points to rising demand for faster, more scalable and more consistent production methods.

What happened: - The Business Research Company released its Continuous Bioprocessing Global Market Report 2026, covering market size, trends and forecasts through 2035. - The report puts the market at $0.38 billion in 2025 and $0.46 billion in 2026. - The report forecasts the market will reach $1.01 billion by 2030. - North America held the largest market share in 2025. - Asia-Pacific is expected to grow the fastest خلال the forecast period.

The details: - Continuous bioprocessing uses an unbroken flow of materials that integrates upstream and downstream operations. - The process can combine cultivation, separation, purification and product recovery in a single workflow. - Key benefits include higher production efficiency, more consistent product quality, shorter processing time and lower operating costs. - Growth in 2026 is tied to rising demand for biologics manufacturing, broader use of biopharmaceutical production technologies, expansion in monoclonal antibody output, more biotechnology research investment and efforts to cut manufacturing costs. - Growth through 2030 is linked to demand for cell and gene therapies, investment in bioprocessing infrastructure, use of automated process monitoring and expansion of personalized medicine. - The report highlights rising use of single-use systems, integrated upstream and downstream workflows, higher-yield biomanufacturing, tighter process consistency and broader use of continuous production methods. - The market coverage spans Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - New report features include market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables. - The report also includes a free sample download and a full report page: Download a free sample and View the full report.

Between the lines: - Personalized medicine appears to be a key demand engine because it favors small-batch, high-value production with tighter quality control. - The market’s growth rate suggests investors and manufacturers are prioritizing flexibility and efficiency over traditional batch processing. - The report’s added forecasting tools and scoring models signal growing interest in decision support for capital planning and market entry.

What's next: - The market is expected to keep expanding as more drug developers adopt continuous production for complex therapies. - The strongest growth is likely to come from Asia-Pacific as biomanufacturing capacity and advanced therapies scale up. - Future adoption will likely center on automation, integrated workflows and single-use technologies.

The bottom line: - Continuous bioprocessing is becoming a key manufacturing model for the next wave of biologics and personalized treatments.